Prevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019

[1]  Feng Li,et al.  Risk assessment of venous thromboembolism and bleeding in COVID-19 patients , 2020 .

[2]  D. Wichmann.  Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 , 2020, Annals of Internal Medicine.

[3]  F. Franceschi,et al.  Venous thromboembolism in critically ill patients affected by ARDS related to COVID-19 in Northern-West Italy. , 2020, European review for medical and pharmacological sciences.

[4]  Arthur L. Allen,et al.  Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum , 2020, Journal of Thrombosis and Thrombolysis.

[5]  V. Fuster,et al.  Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19 , 2020, Journal of the American College of Cardiology.

[6]  Mickaël Ohana,et al.  High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study , 2020, Intensive Care Medicine.

[7]  D. Gommers,et al.  Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis , 2020, Thrombosis Research.

[8]  R. Schwartzstein,et al.  Covid-19 - A Reminder to Reason. , 2020, The New England journal of medicine.

[9]  A. Lavinio,et al.  Thrombotic complications of patients admitted to intensive care with COVID-19 at a teaching hospital in the United Kingdom , 2020, Thrombosis Research.

[10]  P. Prandoni,et al.  Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience , 2020, Journal of Thrombosis and Haemostasis.

[11]  Matthijs Oudkerk,et al.  Diagnosis, Prevention, and Treatment of Thromboembolic Complications in COVID-19: Report of the National Institute for Public Health of the Netherlands , 2020, Radiology.

[12]  Nils Kucher,et al.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy , 2020, Thrombosis Research.

[13]  S. Susen,et al.  Pulmonary Embolism in COVID-19 Patients: Awareness of an Increased Prevalence. , 2020, Circulation.

[14]  Á. Cequier,et al.  [Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]. , 2020, Revista espanola de cardiologia.

[15]  Á. Cequier,et al.  Recomendaciones sobre el tratamiento antitrombótico durante la pandemia COVID-19. Posicionamiento del Grupo de Trabajo de Trombosis Cardiovascular de la Sociedad Española de Cardiología , 2020, Revista Española de Cardiología.

[16]  M. Ramakers,et al.  High incidence of venous thromboembolic events in anticoagulated severe COVID‐19 patients , 2020, Journal of Thrombosis and Haemostasis.

[17]  P. Navalesi,et al.  COVID-19-Related Severe Hypercoagulability in Patients Admitted to Intensive Care Unit for Acute Respiratory Failure , 2020, Thrombosis and Haemostasis.

[18]  Yaolong Chen,et al.  Prevention and Treatment of Venous Thromboembolism Associated with Coronavirus Disease 2019 Infection: A Consensus Statement before Guidelines , 2020, Thrombosis and Haemostasis.

[19]  L. Beenen,et al.  Incidence of venous thromboembolism in hospitalized patients with COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[20]  W. Brady,et al.  Cardiovascular complications in COVID-19 , 2020, The American Journal of Emergency Medicine.

[21]  L. Menicanti,et al.  The procoagulant pattern of patients with COVID‐19 acute respiratory distress syndrome , 2020, Journal of Thrombosis and Haemostasis.

[22]  E. Marone,et al.  Upsurge of deep venous thrombosis in patients affected by COVID-19: Preliminary data and possible explanations , 2020, Journal of Vascular Surgery: Venous and Lymphatic Disorders.

[23]  Yutao Guo,et al.  COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up , 2020, Journal of the American College of Cardiology.

[24]  B. Lämmle,et al.  Severe COVID-19 infection associated with endothelial activation , 2020, Thrombosis Research.

[25]  M. Cushman,et al.  DOACs vs LMWHs in hospitalized medical patients: a systematic review and meta-analysis that informed 2018 ASH guidelines. , 2020, Blood advances.

[26]  Shu-Yuan Xiao,et al.  Pathological study of the 2019 novel coronavirus disease (COVID-19) through postmortem core biopsies , 2020, Modern Pathology.

[27]  D. Gommers,et al.  Incidence of thrombotic complications in critically ill ICU patients with COVID-19 , 2020, Thrombosis Research.

[28]  Feng Wang,et al.  Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[29]  W. Liang,et al.  Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19 , 2020, The Lancet Haematology.

[30]  W. Ageno,et al.  COVID-19 and haemostasis: a position paper from Italian Society on Thrombosis and Haemostasis (SISET). , 2020, Blood transfusion = Trasfusione del sangue.

[31]  L. Alberio,et al.  Thromboprophylaxis and laboratory monitoring for in-hospital patients with Covid-19 - a Swiss consensus statement by the Working Party Hemostasis. , 2020, Swiss medical weekly.

[32]  Dengju Li,et al.  Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy , 2020, Journal of Thrombosis and Haemostasis.

[33]  A. Falanga,et al.  ISTH interim guidance on recognition and management of coagulopathy in COVID‐19 , 2020, Journal of Thrombosis and Haemostasis.

[34]  D. Lillicrap.  Disseminated intravascular coagulation in patients with 2019‐nCoV pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[35]  P. Roy,et al.  Validation of risk assessment models predicting venous thromboembolism in acutely ill medical inpatients: A cohort study , 2020, Journal of thrombosis and haemostasis : JTH.

[36]  L. Mbuagbaw,et al.  Prognostic factors for VTE and Bleeding in Hospitalized Medical Patients: a systematic review and meta-analysis. , 2020, Blood.

[37]  Dengju Li,et al.  Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia , 2020, Journal of Thrombosis and Haemostasis.

[38]  G. Raskob,et al.  Modified IMPROVE VTE Risk Score and Elevated D-Dimer Identify a High Venous Thromboembolism Risk in Acutely Ill Medical Population for Extended Thromboprophylaxis , 2020, TH Open.

[39]  M. Humbert,et al.  2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS): supplementary data , 2019 .

[40]  T. van der Poll,et al.  Diagnosis and management of sepsis‐induced coagulopathy and disseminated intravascular coagulation , 2019, Journal of thrombosis and haemostasis : JTH.

[41]  G. Guyatt,et al.  Evidence vs Consensus in Clinical Practice Guidelines. , 2019, JAMA.

[42]  M. Vaduganathan,et al.  Extended prophylaxis for venous thromboembolism after hospitalization for medical illness: A trial sequential and cumulative meta-analysis , 2019, PLoS medicine.

[43]  S. Cannegieter,et al.  Validation of risk assessment models for venous thrombosis in hospitalized medical patients , 2019, Research and Practice in Thrombosis and Haemostasis.

[44]  Y. Mehta,et al.  Adjunctive Intermittent Pneumatic Compression for Venous Thromboprophylaxis , 2019, The New England journal of medicine.

[45]  F. Dentali,et al.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients. , 2018, Blood advances.

[46]  G. Raskob,et al.  Rivaroxaban for Thromboprophylaxis after Hospitalization for Medical Illness , 2018, The New England journal of medicine.

[47]  R. Yusen,et al.  The IMPROVEDD VTE Risk Score: Incorporation of D-Dimer into the IMPROVE Score to Improve Venous Thromboembolism Risk Stratification , 2017, TH Open.

[48]  V. Chopra,et al.  Validation of Risk Assessment Models of Venous Thromboembolism in Hospitalized Medical Patients. , 2016, The American journal of medicine.

[49]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[50]  P. Dobesh,et al.  Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism , 2016, Journal of Thrombosis and Thrombolysis.

[51]  R. Pendleton,et al.  VTE Incidence and Risk Factors in Patients With Severe Sepsis and Septic Shock. , 2015, Chest.

[52]  W. Ageno,et al.  Recurrent venous thromboembolism in anticoagulated patients with cancer: management and short‐term prognosis , 2015, Journal of thrombosis and haemostasis : JTH.

[53]  A. Eichorn,et al.  External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System , 2014, Journal of the American Heart Association.

[54]  E. Moore,et al.  Fibrinolysis for intermediate-risk pulmonary embolism. , 2014, The New England journal of medicine.

[55]  N. Heddle,et al.  External validation of a risk assessment model for venous thromboembolism in the hospitalised acutely-ill medical patient (VTE-VALOURR) , 2014, Thrombosis and Haemostasis.

[56]  A. Delluc,et al.  Dose escalation of low molecular weight heparin in patients with recurrent cancer-associated thrombosis. , 2014, Thrombosis research.

[57]  A. Mebazaa,et al.  D‐dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial , 2014, Journal of thrombosis and haemostasis : JTH.

[58]  D. Aujesky,et al.  Multicentre validation of the Geneva Risk Score for hospitalised medical patients at risk of venous thromboembolism , 2013, Thrombosis and Haemostasis.

[59]  G. Raskob,et al.  Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. , 2013, The New England journal of medicine.

[60]  D. Cook,et al.  Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials* , 2013, Critical care medicine.

[61]  Giancarlo Agnelli,et al.  Oral apixaban for the treatment of acute venous thromboembolism. , 2013, The New England journal of medicine.

[62]  H. Bitterman,et al.  Venous thromboembolism and the utility of the Padua Prediction Score in patients with sepsis admitted to internal medicine departments , 2013, Journal of thrombosis and haemostasis : JTH.

[63]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[64]  A. Amin,et al.  Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. , 2012, Journal of hospital medicine.

[65]  Elie A Akl,et al.  Prevention of VTE in Nonsurgical Patients Antithrombotic Therapy and Prevention of Thrombosis , 9 th ed : American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2013 .

[66]  A. Turpie,et al.  Predictive and associative models to identify hospitalized medical patients at risk for VTE. , 2011, Chest.

[67]  G. Guyatt,et al.  Dalteparin versus unfractionated heparin in critically ill patients. , 2011, The New England journal of medicine.

[68]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[69]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[70]  P. Prandoni,et al.  A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua Prediction Score , 2010, Journal of thrombosis and haemostasis : JTH.

[71]  M. Rodger,et al.  Dose escalation of low molecular weight heparin to manage recurrent venous thromboembolic events despite systemic anticoagulation in cancer patients , 2009, Journal of thrombosis and haemostasis : JTH.

[72]  A. Shorr,et al.  Venous thromboembolism in critically ill patients , 2008, Thrombosis and Haemostasis.

[73]  M. Prins,et al.  Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial , 2006, BMJ : British Medical Journal.

[74]  J. Hirsh,et al.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[75]  S. Goldhaber,et al.  Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients , 2004, Circulation.

[76]  M. Kovacs,et al.  Extended outpatient therapy with low molecular weight heparin for the treatment of recurrent venous thromboembolism despite warfarin therapy. , 2001, The American journal of medicine.

[77]  R. Pordes,et al.  Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. , 2000, American journal of respiratory and critical care medicine.

[78]  A. Turpie,et al.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. , 1999, The New England journal of medicine.

[79]  Radcliffe Infirmary,et al.  Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients , 1994, BMJ.